Ronald van Vollenhoven

Professor Ronald van Vollenhoven’s research interests focus around the development and systematic evaluation of biological and immunomodulatory treatments for the rheumatic diseases, including B-cell targeting therapies. He has been principal or co-investigator in many clinical trials of novel therapies in rheumatic diseases, including B-cell directed therapies such as rituximab, belimumab, atacicept, tabalumab and epratuzumab. With his co-workers he has designed and carried out investigator-initiated trials (including SWEFOT, ADMIRE, DOSERA, and NORD-STAR), and (co-)developed registries for further “real-world” evaluation of biologicals (STURE, CERERRA, IRBIS), supporting research projects relating to clinical efficacy, pharmacology, outcomes and pharmacoeconomics.


Amsterdam Rheumatology and immunology Center ARC, AMC, Reade, VUMC, Amsterdam, The Netherlands


Chatzidionysiou K, Lie E, Lukina G, Hetland ML, Hauge EM, Pavelka K, Gabay C, Scherer A, Nordstrom D, Canhao H, et al. Rituximab Retreatment in Rheumatoid Arthritis in a Real-life Cohort: Data from the CERERRA Collaboration. J Rheumatol. 2017.

Ryden-Aulin M, Boumpas D, Bultink I, Callejas Rubio JL, Caminal-Montero L, Castro A, Colodro Ruiz A, Doria A, Dorner T, Gonzalez-Echavarri C, et al. Off-label use of rituximab for systemic lupus erythematosus in Europe. Lupus Sci Med. 2016.

Chatzidionysiou K, Lie E, Nasonov E, Lukina G, Hetland ML, Tarp U, Ancuta I, Pavelka K, Nordstrom DC, Gabay C, et al. Erratum to: Effectiveness of two different doses of rituximab for the treatment of rheumatoid arthritis in an international cohort: data from the CERERRA collaboration. Arthritis Res Ther. 2016.

van Vollenhoven RF, Petri M, Wallace DJ, Roth DA, Molta CT, Hammer AE, Tang Y, Thompson A. Cumulative Corticosteroid Dose Over Fifty-Two Weeks in Patients With Systemic Lupus Erythematosus: Pooled Analyses From the Phase III Belimumab Trials. Arthritis Rheumatol. 2016.

Merrill JT, van Vollenhoven RF, Buyon JP, Furie RA, Stohl W, Morgan-Cox M, Dickson C, Anderson PW, Lee C, Berclaz PY, et al. Efficacy and safety of subcutaneous tabalumab, a monoclonal antibody to B-cell activating factor, in patients with systemic lupus erythematosus: results from ILLUMINATE-2, a 52-week, phase III, multicentre, randomised, double-blind, placebo-controlled study. Ann Rheum Dis. 2016.

van Vollenhoven RF, Wax S, Li Y, Tak PP. Safety and efficacy of atacicept in combination with rituximab for reducing the signs and symptoms of rheumatoid arthritis: a phase II, randomized, double-blind, placebo-controlled pilot trial. Arthritis Rheumatol. 2015.

van Vollenhoven RF, Emery P, Bingham CO, 3rd, Keystone EC, Fleischmann RM, Furst DE, Tyson N, Collinson N, Lehane PB. Long-term safety of rituximab in rheumatoid arthritis: 9.5-year follow-up of the global clinical trial programme with a focus on adverse events of interest in RA patients. Ann Rheum Dis. 2013.

van Vollenhoven RF, Petri MA, Cervera R, Roth DA, Ji BN, Kleoudis CS, Zhong ZJ, Freimuth W. Belimumab in the treatment of systemic lupus erythematosus: high disease activity predictors of response. Ann Rheum Dis. 2012.


Niels Franke: Molecular mechanisms of bortezomib resistance in acute leukemia. (VU University Amsterdam) Awarded: 2017

Adrian Levitsky: Predicting and monitoring disease course in rheumatoid arthritis: imaging, biomarkers, risk factors, and integrative medicine. (The Karolinska Institute) Awarded: 2017

Cecilia Lourdudoss: Association between diet and treatment results in RA and SLE. (The Karolinska Institute) Awarded: 2016

Nienke Lesuis: Quality of care in rheumatology. Translating evidence into practice. (Radboud University) Awarded: 2016

Noortje van Herwaarden: Individualised biological treatment in Rheumatoid Arthritis. (Utrecht University) Awarded: 2015

Hamed Rezaei: The role of X-ray imaging and musculoskeletal ultrasound in the diagnosis and management of Rheumatoid Arthritis. (The Karolinska Institute) Awarded: 2014

Katerina Chatzidionysiou: Biological Therapy in Rheumatoid Arthritis – Epidemiological Studies. (The Karolinska Institute) Awarded 2014

Jenny Augustsson: Biological therapies – Treatment outcome in RA-patients: Quality of life, health economy, and pharmacotherapy. (The Karolinska Institute) Awarded: 2010

Thorunn Jonsdottir: B-cell depletion in systemic lupus erythematosus. (The Karolinska Institute) Awarded: 2009